SEC 13F Intelligence

Managers / Q3 2024 · view latest →

Aquilo Capital Management, LLC

CIK 0001591986 · ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, SAN FRANCISCO, CA, 94129 · 415-635-0140

Reported Value
$132M
Q3 2024
Positions
14
Filings on Record
27
2019–present window
Filed
Nov 14, 2024
original filing

Summary

Aquilo Capital Management, LLC reported $132M in U.S.-listed holdings across 14 positions for Q3 2024.

Its largest position, ARWR, represents 11.7% of the portfolio.

Compared with Q2 2024, the fund opened 1 new position and exited 0.

Portfolio Metrics

Turnover
+15.8%
vs prior filed quarter
Top-10 Concentration
+60.2%
share of reported value
Largest Position
+11.7%
Arrowhead Pharmaceuticals In

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $226MQ1 ’19Q2 ’19: $288MQ3 ’19: $142MQ4 ’19: $266MQ1 ’20: $257MQ1 ’20Q2 ’20: $496MQ3 ’20: $945MQ4 ’20: $481MQ1 ’21: $553MQ1 ’21Q2 ’21: $385MQ3 ’21: $551MQ4 ’21: $882MQ1 ’22: $680MQ1 ’22Q2 ’22: $293MQ3 ’22: $277MQ4 ’22: $266MQ1 ’23: $241MQ1 ’23Q2 ’23: $180MQ3 ’23: $110MQ4 ’23: $160MQ1 ’24: $133MQ1 ’24Q2 ’24: $104MQ3 ’24: $132MQ4 ’24: $66MQ1 ’25: $56MQ1 ’25Q2 ’25: $0Q3 ’25: $0filingsflow.com

Portfolio Composition

By security type
Common Stock: 50.5%ETP: 32.6%Other: 9.4%ADR: 7.5%
  • Common Stock · 50.5% · $67M
  • ETP · 32.6% · $43M
  • Other · 9.4% · $12M
  • ADR · 7.5% · $10M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
SPYSPDR S&P 500 ETF TRNEW+75.0K75.0K+$43M$43M
IMMATICS N.VADDED+133.5K333.5K+$1M$4M
SLNSILENCE THERAPEUTICS PLCTRIMMED−183.0K317.2K−$4M$6M
KYMRKYMERA THERAPEUTICS INCTRIMMED−120.0K208.7K+$66,827$10M
MERUS N VTRIMMED−30.3K117.9K−$3M$6M
BCYCBICYCLE THERAPEUTICS PLCADDED+25.2K181.9K+$945,200$4M
ARWRARROWHEAD PHARMACEUTICALS INTRIMMED−112.7K795.8K−$8M$15M
ARVNARVINAS INCTRIMMED−40.0K388.8K−$2M$10M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2024

13 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1ARWRARROWHEAD PHARMACEUTICALS INhistory →COM11.69%$15M795.8K
2BLUEPRINT MEDICINES CORPCOM8.74%$12M124.6K
3KYMRKYMERA THERAPEUTICS INChistory →COM7.49%$10M208.7K
4RGNXREGENXBIO INChistory →COM7.40%$10M930.7K
5ARVNARVINAS INChistory →COM7.26%$10M388.8K
6MERUS N VCOM4.46%$6M117.9K
7SLNSILENCE THERAPEUTICS PLChistory →ADS4.37%$6M317.2K
8BCYCBICYCLE THERAPEUTICS PLChistory →SPONSORED ADS3.12%$4M181.9K
9IMMATICS N.VSHS2.89%$4M333.5K
10ADICET BIO INCCOM2.76%$4M2.53M
11DTILPRECISION BIOSCIENCES INChistory →COM NEW2.59%$3M381.8K
12RPTXREPARE THERAPEUTICS INChistory →COM2.58%$3M989.4K
13SUTRO BIOPHARMA INCCOM2.00%$3M762.5K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2025$01Nov 12, 202513F-HRchanges · EDGAR ↗
Q2 2025$01Aug 6, 202513F-HRchanges · EDGAR ↗
Q1 2025$56M13May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$66M15Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$132M14Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$104M13Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$133M10May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$160M10Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$110M12Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$180M13Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$241M12May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$266M13Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$277M15Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$293M13Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$680M14May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$882M14Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$551M14Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$385M15Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$553M17May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$481M17Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$945M17Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$496M14Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$257M14May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$266M12Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$142M11Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$288M13Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$226M14May 15, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.